Physician profile
Dan E Mccarty
NPI 1780641613
$979.96
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2022: $13.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $195.03 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $148.73 | 2019 | |
| Novo Nordisk INC | $137.82 | 2019 | |
| Amgen INC. | $131.04 | 2019-2022 | |
| Lilly USA, LLC | $115.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.90 | 2019 | |
| Radius Health, INC. | $35.14 | 2019 | |
| Merck Sharp & Dohme LLC | $33.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.99 | 2019 | |
| Glaxosmithkline, LLC. | $23.23 | 2019 | |
| Abbvie INC. | $22.96 | 2019 | |
| Shire North American Group INC | $16.77 | 2019 | |
| Allergan, INC. | $15.04 | 2019 | |
| Amarin Pharma, INC. | $13.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.91 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.